Ulixertinib is named as an intervention in 2 current clinical trials in our Norway, Mexico, Israel, Egypt, Canada and Australia registers. None are recruiting at the moment. All registered phases are Phase 2. The lead sponsor is National Cancer Institute (NCI). The most-studied condition is Advanced Malignant Solid Neoplasm.
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3590106, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3), ligand 9210, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02465060 · ClinicalTrials.gov ↗ · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma
|
Phase 2 | Active, closed | National Cancer Institute (NCI) | Norway, Mexico, Israel, Egypt |
|
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
NCT03155620 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma
|
Phase 2 | Active, closed | National Cancer Institute (NCI) | Canada, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Norway | 1 | 0 |
| Clinical trials in Mexico | 1 | 0 |
| Clinical trials in Israel | 1 | 0 |
| Clinical trials in Egypt | 1 | 0 |
| Clinical trials in Canada | 1 | 0 |
| Clinical trials in Australia | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Norway, Mexico, Israel, Egypt, Canada and Australia registers name Ulixertinib (also registered as BVD-523) as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
The lead sponsor is National Cancer Institute (NCI). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ulixertinib works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ulixertinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ulixertinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.